昭衍新藥(06127.HK)境外全資子公司參與投資設立基金 認繳出資800萬美元
昭衍新藥(06127.HK)公布,為充分借助專業投資機構在投資研發能力及項目資源上的獨特優勢,夯實產業基礎,昭衍新藥境外全資子公司昭衍特拉華與Pablo Hill Capital Management, LLC.及Vcanbio USA
Healthcare Venture Fund, L.P. 共同出資發起設立Pablo Hill Venture Fund One, L.P基金。基金以有限合夥企業形式設立,投資領域包括但不限於生物科技、製藥、醫療器械、生命科學等,認繳出資總額為2,000萬美元。昭衍特拉華擬作為有限合夥人認繳出資800萬美元,佔本有限合夥40%份額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.